Insight Molecular Diagnostics Inc. — Director's Dealing 2021

Feb 9, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2021-02-05

Reporting Person: BROADWOOD PARTNERS, L.P. (10% Owner)
Reporting Person: BROADWOOD CAPITAL INC (10% Owner)
Reporting Person: BRADSHER NEAL C (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-05	Common Stock, no par value	P	600000	$4.50	Acquired	16776484	Direct
2021-02-05	Common Stock, no par value	P	0	—	Acquired	16776484	Indirect

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock, no par value	3145	Direct

Footnotes

F1: The reported securities are directly owned by Broadwood Partners, L.P. and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners, L.P. and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: These securities are directly owned by Neal C. Bradsher.